Rheumatoid arthritis

Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis

Ann Rheum DisPublished Mechanistic study

An erratum to this article was published (Ann Rheum Dis, Nov 2023 ↗)

Authors' conclusion

Our study highlights the role of cytokine-activated FLS in orchestrating inflammation-associated synovial pathotypes providing novel insights into disease mechanisms of RA.

Study context

Population
Patients with rheumatoid arthritis (RA): Fibroblast-like synoviocytes (FLS) and autologous peripheral CD4+ T cells
Comparison
Cytokine-activated vs unstimulated FLS co-cultured with autologous peripheral CD4+ T cells
Outcome
FLS-T cell interaction and synovial pathotype signatures
Methodological detailsautomated high-content fluorescence microscopy, flow cytometry, RNA-Seq, integration with public transcriptomic data, knock-down experiments
  • Automated high-content fluorescence microscopy
  • Flow cytometry
  • RNA-Seq
  • Integration with public transcriptomic data
  • Knock-down experiments

Main finding

As reported in the abstract

  • Cytokine stimulation, especially TNF-α, enhanced FLS-T cell interaction, causing contact-dependent T cell activation, proliferation and differentiation
  • Cytokine-activated FLS signatures significantly enriched in lymphoid-rich or leucocyte-rich RA synovial pathotypes, most prominent for TNF-α
  • FLS cytokine signatures correlated with number of infiltrating CD4+ T cells in RA synovial tissue
  • ICAM1 on FLS identified as important mediator of TNF-mediated FLS-T cell interaction; ICAM1 and its receptors overexpressed in TNF-treated FLS and co-cultured T cells
  • Knock-down of ICAM1 in FLS reduced TNF-mediated FLS-T cell interaction

Original publication

Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis. Ann Rheum Dis. Published 21 June 2023. doi:10.1136/ard-2022-223396

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.